Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02054520 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy Study for Patients With Stage IV Melanoma
A Phase 2 study, sponsored by NewLink Genetics Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT02054520 is a Phase 2 study that was terminated before completion, run by NewLink Genetics Corporation. The registered enrollment target is 47 participants.
The verdict
NCT02054520, a Phase 2 study, was terminated before completion, sponsored by NewLink Genetics Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effectiveness of immune checkpoint inhibitors (drugs called ipilimumab, nivolumab, or pembrolizumab), either given alone, or in combination with the experimental immunotherapy drug, dorgenmeltucel-L, for melanoma. We hypothesize that this form of combinatorial immunotherapy will result in tumor stabilization or shrinkage, significant prolongation of progression-free, disease-free or overall survival compared to the use of immune checkpoint inhibitors alone.
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG HyperAcute®-Melanoma (HAM) Immunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2014-06 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02054520
The ClinicalTrials.gov registry entry for NCT02054520 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02054520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02054520 about?
NCT02054520 is a clinical study titled "Immunotherapy Study for Patients With Stage IV Melanoma". The purpose of this study is to examine the effectiveness of immune checkpoint inhibitors (drugs called ipilimumab, nivolumab, or pembrolizumab), either given alone, or in combination with the experimental immunotherapy drug, dorgenmeltucel-L, for melanoma. We hypothesize that this form of combinato...
What is the current status of trial NCT02054520?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2014-06. Estimated completion is 2021-01-05.
What interventions are being tested in trial NCT02054520?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), HyperAcute®-Melanoma (HAM) Immunotherapy (DRUG).
Who is sponsoring clinical trial NCT02054520?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.